Last updated: July 31, 2026
OCUSERT PILO-20 is a once-weekly pilocarpine ocular insert developed by Alza for glaucoma and ocular-hypertension treatment. The product delivered pilocarpine at approximately 20 micrograms per hour through a reservoir insert placed in the conjunctival sac. It is no longer an active commercial product, has no meaningful current clinical-trial pipeline, and has no credible standalone market-growth outlook. Its commercial relevance is historical and competitive: modern pilocarpine drops, sustained-release delivery systems, and newer presbyopia products have replaced the product’s original value proposition.
What is OCUSERT PILO-20?
OCUSERT PILO-20 was a controlled-release ocular therapeutic system containing pilocarpine. The insert was designed to remain in the eye for approximately seven days and provide continuous drug delivery, compared with multiple daily administrations required for conventional pilocarpine eye drops.
| Attribute |
OCUSERT PILO-20 |
| Active ingredient |
Pilocarpine |
| Drug class |
Cholinergic miotic |
| Dosage form |
Ocular insert |
| Nominal delivery rate |
Approximately 20 micrograms per hour |
| Intended duration |
Approximately one week |
| Historical indications |
Glaucoma and ocular hypertension |
| Original technology developer |
Alza Corporation |
| Current commercial status |
Discontinued; no active marketed product identified |
| Current clinical development |
No active development program identified |
| Current market position |
Historical product; no standalone commercial market |
Pilocarpine reduces intraocular pressure by increasing aqueous humor outflow through cholinergic stimulation. Its clinical use has declined because of dosing burden, visual side effects, accommodative effects, brow ache, induced myopia, and the availability of prostaglandin analogues, beta blockers, alpha agonists, carbonic anhydrase inhibitors, laser treatment, and surgical interventions.
What is the FDA and regulatory status of OCUSERT PILO-20?
OCUSERT PILO-20 is not an actively marketed FDA product. Historical approval records and product labeling identify OCUSERT as an FDA-approved pilocarpine ocular delivery system, but the product has been discontinued and is not a current commercial treatment option in the United States.
The product should be distinguished from currently available pilocarpine ophthalmic solutions and newer pilocarpine products approved for different indications. FDA approval of a pilocarpine solution does not preserve approval or commercial status for the OCUSERT insert.
| Regulatory question |
Status |
| FDA approval history |
Historical FDA approval for pilocarpine ocular insert technology |
| Current U.S. marketing |
No active commercial supply identified |
| Current FDA clinical program |
None identified |
| Current prescribing availability |
Not generally available as a marketed product |
| Current Orange Book relevance |
Historical/discontinued product status rather than an active reference-product platform |
| Current regulatory pathway |
No active 505(b)(2) or new drug application program identified |
FDA records distinguish discontinued products from products that have been withdrawn for safety or efficacy reasons. Discontinuation alone does not establish that a drug was unsafe or ineffective. The commercial discontinuation of OCUSERT PILO-20 is consistent with declining clinical demand and product-use limitations rather than evidence of a current regulatory safety dispute.[1]
Are there clinical trials for OCUSERT PILO-20?
No active clinical-trial program for OCUSERT PILO-20 has been identified in current public trial registries. The product’s clinical evidence base is historical and includes studies conducted during the development and commercialization of ocular inserts and pilocarpine therapy.
The original clinical rationale centered on improving adherence through continuous delivery. Historical studies evaluated intraocular pressure control, tolerability, retention of the insert, ease of placement and removal, and comparison with pilocarpine eye drops.
| Trial category |
Current status |
| Historical glaucoma efficacy studies |
Completed |
| Historical ocular-hypertension studies |
Completed |
| Comparative studies versus pilocarpine drops |
Completed or historical |
| New glaucoma trials |
None identified |
| New presbyopia trials for OCUSERT |
None identified |
| Pediatric trials |
None identified |
| Biosimilar or follow-on biologic trials |
Not applicable |
| Registration-enabling trials |
No active program |
OCUSERT PILO-20 is a small-molecule drug-delivery product, not a biologic. Biosimilar competition therefore does not apply. Any modern follow-on would likely require a generic drug, a 505(b)(2) application, or a combination-product development strategy depending on the delivery system and the extent of reliance on historical data.
What patents protected OCUSERT PILO-20?
The commercial protection for OCUSERT PILO-20 was likely based on a combination of platform patents, formulation claims, device architecture, and manufacturing know-how. The relevant intellectual-property estate is now historical because the product was developed decades ago.
The principal technology categories were:
- Ocular insert geometry and placement.
- Drug reservoirs and rate-controlling membranes.
- Pilocarpine-containing formulations.
- Controlled release over multiple days.
- Manufacturing and assembly methods.
- Packaging and storage systems.
The core patents would have been subject to the pre-1995 patent-term rules, terminal disclaimers, maintenance-fee requirements, and expiration based on the applicable filing and grant dates. Any original patent protection for the first-generation OCUSERT platform has expired. No commercially meaningful patent barrier is expected to remain around the original PILO-20 concept.
| IP category |
Current commercial significance |
| Original OCUSERT platform patents |
Expected expired |
| Pilocarpine composition claims |
Expected expired or weak |
| Seven-day ocular insert claims |
Expected expired |
| Manufacturing know-how |
Potentially confidential, but no established commercial barrier |
| Modern sustained-release pilocarpine systems |
May have separate, newer patent estates |
| Trade dress and branding |
No material protection for a discontinued product |
A new developer could still seek patents for a redesigned pilocarpine insert, improved retention system, hydrogel, intracameral depot, punctal delivery system, or combination product. Those patents would protect the new delivery system rather than revive the expired OCUSERT estate.
What formulation patents could affect a modern OCUSERT PILO-20 follow-on?
A modern follow-on would face formulation and device issues rather than legacy composition-of-matter protection. Relevant claims could cover:
- Drug loading and release kinetics.
- Membrane permeability.
- Insert dimensions and flexibility.
- Retention in the conjunctival sac.
- Reduced migration or expulsion.
- Sterility and packaging.
- Preservative-free formulations.
- Compatibility with contact lenses.
- Improved tolerability.
- Combination treatment with other glaucoma agents.
The principal technical barrier is not simply making pilocarpine release slowly. A successful product must remain in place, avoid corneal injury, maintain predictable drug exposure, and permit reliable removal. These requirements can support new device and formulation patents, but they also increase development and manufacturing complexity.
When did OCUSERT PILO-20 lose exclusivity?
The product’s original exclusivity expired long before the current pharmaceutical market. OCUSERT PILO-20 has no remaining meaningful regulatory exclusivity, pediatric exclusivity, orphan exclusivity, or active patent term associated with its original commercial launch.
| Exclusivity type |
Current status |
| New chemical entity exclusivity |
Expired |
| Original platform patent term |
Expired |
| Formulation patent term |
Historical and expected expired |
| Pediatric exclusivity |
None identified |
| Orphan exclusivity |
Not applicable |
| Data exclusivity |
Expired |
| Current market exclusivity |
None |
The absence of exclusivity does not by itself create a generic market. A generic manufacturer would need a viable reference product, suitable bioequivalence or comparative clinical strategy, reproducible manufacturing, and sufficient commercial demand.
Which companies are challenging OCUSERT PILO-20?
No active Paragraph IV litigation or meaningful generic challenge directed specifically at OCUSERT PILO-20 has been identified. The product is not a current commercial target in the way that an actively marketed branded ophthalmic drug would be.
Paragraph IV litigation is also unlikely to be commercially relevant because:
- The product is discontinued.
- Its core patents are historical.
- Current competitors generally use different dosage forms.
- Pilocarpine ophthalmic solutions are already available as generic products.
- A new sustained-release insert would likely require new technical development rather than a direct substitution.
Potential competitors are therefore product-class competitors, not direct challengers to OCUSERT’s legacy patents.
How does OCUSERT PILO-20 compare with current pilocarpine products?
| Product or class |
Delivery |
Primary commercial use |
Competitive position |
| OCUSERT PILO-20 |
Weekly ocular insert |
Historical glaucoma treatment |
Discontinued |
| Generic pilocarpine drops |
Multiple daily drops |
Glaucoma, ocular indications |
Low-cost standard |
| Isopto Carpine and related brands |
Pilocarpine drops |
Glaucoma |
Limited branded position |
| VUITY |
Pilocarpine 1.25% ophthalmic solution |
Presbyopia |
Modern branded pilocarpine product |
| Prostaglandin analogues |
Once-daily drops |
Glaucoma |
Strong first-line competition |
| Sustained-release glaucoma implants |
Depot or implant delivery |
Glaucoma |
Device-based alternative |
VUITY, marketed by AbbVie through its eye-care business, expanded pilocarpine’s commercial relevance in presbyopia but does not represent a revival of the OCUSERT insert. Its formulation, indication, clinical evidence, labeling, and patent estate are distinct.[2]
What is the market outlook for OCUSERT PILO-20?
The standalone market outlook is effectively zero because OCUSERT PILO-20 is not an active commercial product. Revenue projections for the original product are therefore not appropriate.
The addressable opportunity exists only for a redesigned sustained-release pilocarpine product. Such a product would compete in two separate markets:
- Glaucoma and ocular hypertension.
- Pharmacologic presbyopia treatment.
The glaucoma market is larger but highly competitive. Pilocarpine has a limited role because of tolerability and visual side effects. The presbyopia market offers a newer commercial opportunity, but demand depends on duration of effect, patient selection, dosing convenience, and competition from other miotic agents and corrective technologies.
| Scenario |
Commercial assessment |
| Re-launch of original OCUSERT PILO-20 |
Not commercially realistic |
| Generic reproduction of legacy insert |
Low probability |
| New sustained-release pilocarpine insert |
Technically possible, high development risk |
| Presbyopia-focused insert |
Greater differentiation potential |
| Glaucoma-focused depot product |
Larger clinical need, difficult competition |
| Licensing of legacy OCUSERT IP |
Limited value unless linked to know-how or archived manufacturing assets |
A new product would likely require substantial investment in human factors, ocular tolerability, retention, sterility, manufacturing validation, and clinical efficacy. The commercial return would depend on achieving a clear advantage over inexpensive pilocarpine drops or branded once-daily therapies.
What manufacturing and intellectual-property barriers remain?
The most important barriers are manufacturing and clinical, not legacy patent exclusivity. A controlled-release ocular insert must meet tight specifications for drug content, release profile, dimensional stability, sterility, packaging, and extractables and leachables.
Manufacturing risks include:
- Batch-to-batch release variability.
- Inconsistent insert placement or retention.
- Drug crystallization or degradation.
- Sterilization-related changes in release kinetics.
- Packaging moisture control.
- Device migration and patient removal problems.
- Scale-up of membrane or reservoir fabrication.
A follow-on manufacturer could avoid expired patents but still face regulatory questions over equivalence. For a complex ocular insert, conventional dissolution testing may not fully predict ocular exposure. The FDA could require comparative clinical data or a more extensive 505(b)(2) package rather than a simple abbreviated application.
What patent litigation and settlement agreements affect OCUSERT PILO-20?
No current patent litigation, Paragraph IV settlement, or commercial settlement agreement materially affecting OCUSERT PILO-20 has been identified. The historical product’s discontinued status reduces the incentive for litigation.
Modern litigation involving pilocarpine products, including presbyopia formulations or new ocular delivery systems, should be analyzed separately. Such cases would not automatically affect the expired OCUSERT platform or create entry restrictions for a new product.
What is the competitive landscape for a new OCUSERT-like product?
The main competitive threats are generic pilocarpine drops, prostaglandin analogues, newer presbyopia therapies, and sustained-release glaucoma systems. A new insert would need a measurable advantage in adherence, duration, tolerability, or visual performance.
The strongest commercial positioning would likely be a product that:
- Requires weekly or less frequent administration.
- Avoids repeated drop instillation.
- Has predictable removal.
- Produces fewer side effects than pilocarpine drops.
- Supports a clear presbyopia or glaucoma indication.
- Can be manufactured at a cost compatible with ophthalmic specialty pricing.
Key Takeaways
- OCUSERT PILO-20 was a historical weekly pilocarpine ocular insert developed by Alza.
- The product is discontinued and has no active clinical-trial program.
- No current Paragraph IV litigation or settlement directly affects OCUSERT PILO-20.
- Original patent and regulatory exclusivity have expired.
- Biosimilar competition is not applicable because pilocarpine is a small molecule.
- Generic pilocarpine drops and newer pilocarpine products are the relevant commercial comparators.
- A re-launch of the original product is commercially unlikely.
- A redesigned sustained-release pilocarpine system could have value, but its protection would need to come from new formulation, device, manufacturing, and method-of-use patents.
- The most credible opportunity is a differentiated product for presbyopia or adherence-sensitive ophthalmic treatment, not a direct revival of the legacy insert.
FAQs About OCUSERT PILO-20
Is OCUSERT PILO-20 still available by prescription?
No active commercial supply has been identified. Current pilocarpine treatment is generally delivered through ophthalmic solutions or newer products with separate formulations and indications.
Did OCUSERT PILO-20 have a seven-day dosing advantage?
Yes. The product was designed to deliver pilocarpine continuously for approximately one week, unlike conventional pilocarpine drops that require repeated daily dosing.
Can a company launch a generic OCUSERT PILO-20 today?
A direct generic launch would be difficult because the original product is discontinued and the dosage form is complex. A new developer would likely need a regulatory strategy supported by comparative performance, manufacturing validation, and potentially clinical data.
Is VUITY the same product as OCUSERT PILO-20?
No. VUITY is a pilocarpine ophthalmic solution approved for presbyopia. OCUSERT PILO-20 was a sustained-release ocular insert historically associated with glaucoma and ocular hypertension.
Does OCUSERT PILO-20 have remaining patent value?
The original patent estate has no apparent remaining exclusionary value. Any commercial value would more likely reside in historical manufacturing knowledge, archived development data, or inspiration for a newly patented ocular delivery system.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and drug labeling. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2021). FDA approves first prescription medication for treatment of presbyopia. https://www.fda.gov/news-events/press-announcements/fda-approves-first-prescription-medication-treatment-presbyopia
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
American Academy of Ophthalmology. (n.d.). Preferred practice pattern: Primary open-angle glaucoma. https://www.aao.org/education/preferred-practice-pattern/primary-open-angle-glaucoma-ppp.enc.
